07:00 , Oct 11, 2010 |  BioCentury  |  Finance

Hallway Chatter

Hallway chatter Companies were busy rolling out their wish lists at the annual BIO Investor Forum in San Francisco last week. Among them was new Executive Chairman Kurt Graves of Intarcia Therapeutics Inc. (formerly BioMedicines...
07:00 , Aug 30, 2010 |  BioCentury  |  Finance

Anchors Aweigh

Anchors aweigh The first $10 million close of a planned $15-$20 million series B round is expected to get Anchor Therapeutics Inc. to at least one, or possibly two, INDs. Anchor (formerly Ascent Therapeutics Inc....
23:32 , Aug 20, 2010 |  BC Extra  |  Financial News

Anchor raises $10 million

Anchor Therapeutics Inc. (Cambridge, Mass.) raised $10 million in a first close of a planned $15-$20 million series B round co-led by existing investors TVM Capital; HealthCare Ventures; and Novartis Option Fund. Anchor (formerly Ascent...
08:00 , Jan 5, 2009 |  BioCentury  |  Emerging Company Profile

Ascent: Scaling Pepducins

Inherent in peptide pharmacology are issues around route of administration, cost and poor pharmacokinetic profiles. Ascent Therapeutics Inc. thinks it has solved some of those problems via its Pepducin technology platform, while maintaining the specificity...
08:00 , Jan 5, 2009 |  BioCentury  |  Emerging Company Profile

Corporate Profile

Ascent Therapeutics Inc. Cambridge, Mass. Technology: Pepducin technology Disease focus: Inflammation, cancer, cardiovascular Clinical status: Preclinical Founded: 2007 by Athan Kuliopulos, Lidija Covic, Michael Webb and Thomas McMurry University collaborators: Tufts Medical Center Corporate partners:...
08:00 , Dec 15, 2008 |  BC Week In Review  |  Company News

Ascent Therapeutics, Novartis deal

Novartis' Novartis Option Fund received an option to Pepducin lipopeptides that Ascent will discover against an undisclosed GPCR target. Ascent is eligible for more than $200 million, including an undisclosed upfront fee and milestones, plus...
08:00 , Dec 8, 2008 |  BC Week In Review  |  Company News

Ascent management update

Ascent Therapeutics Inc. , Cambridge, Mass.   Business: Inflammation, Cancer, Neurology   Hired: Frederick Jones as president, CEO and a director, formerly head of the pharma business unit of Devgen N.V. ; and Stephen Hunt...
08:00 , Dec 8, 2008 |  BC Week In Review  |  Company News

Ascent board of directors update

Ascent Therapeutics Inc. , Cambridge, Mass.   Business: Inflammation, Cancer, Neurology   Appointed: Jens Eckstein, general partner of TVM Capital; founder and CSO Athan Kuliopulos; Chris Mirabelli, managing director of HealthCare Ventures LLC; Lauren Silverman,...